Alvotech tekur þátt í heilbrigðisráðstefnu BofA Securities í Bandaríkjunum
May 02, 2024 07:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið taki þátt í árlegri heilbrigðisráðstefnu BofA Securities, sem haldin verður dagana 14. – 15. maí í Las Vegas, Nevadafylki Bandaríkjanna. Fulltrúar úr...
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024 07:15 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of management would be...
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
May 02, 2024 07:15 ET
|
Alvotech
REYKJAVIK, Iceland, May 02, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024 04:00 ET
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
Alvotech semur við Quallent Pharmaceuticals um markaðssetningu á hliðstæðu við Humira í Bandaríkjunum
April 30, 2024 04:00 ET
|
Alvotech
Alvotech mun framleiða líftæknilyfjahliðstæðu sína í háum styrk með útskiptileika við Humira (adalimumab) fyrir Quallent Pharmaceuticals, dótturfélag Cigna Alvotech (NASDAQ: ALVO) tilkynnti í dag...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024 04:00 ET
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
Alvotech kynnir jákvæða niðurstöðu rannsóknar á sjúklingum sem sýnir sömu klínísku virkni líftæknilyfjahliðstæðunnar AVT05 og Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
Meginendapunktur rannsóknarinnar var uppfylltur, þegar borin var saman klínísk virkni, öryggi og ónæmingarverkun AVT05 og Simponi (golimumab) í sjúklingum með meðallagi alvarlega eða alvarlega...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
April 24, 2024 04:00 ET
|
Alvotech
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid...
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
April 19, 2024 06:10 ET
|
Alvotech
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to...